Aeon Biopharma, INC. (AEON) — 10-Q Filings

10-Q Filings (5)

• AEON Biopharma Narrows Loss, Pivots to Biosimilar Strategy — Nov 14, 2025 Risk: high
  AEON Biopharma, Inc. reported a net loss of $2.085 million for the nine months ended September 30, 2025, a significant improvement from the net income of $39.92
• AEON Shifts Strategy to Biosimilar, Reports Q2 Loss Amid Cash Infusion — Aug 12, 2025 Risk: high
  AEON Biopharma, Inc. reported a net income of $2.453 million for the six months ended June 30, 2025, a significant decrease from $46.094 million in the same per
• AEON Biopharma Files 10-Q for Q1 2025 — May 14, 2025 Risk: medium
  AEON Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Priveterra Acquisition Corp., is in the pharmaceutical
• AEON Biopharma Q3 2024 10-Q Filed — Nov 13, 2024 Risk: medium
  AEON Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $37,159,600 and total liabilities of $39,587,
• AEON Biopharma 10-Q: Assets Rise, Cohen Capital Markets Event — Aug 12, 2024 Risk: medium
  AEON Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $39,122,238 as of June 30, 2024, a slight increase

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX